FDA/CDC

FDA approves abaloparatide for postmenopausal osteoporosis

Publish date: May 2, 2017
By
Lucas Franki

 

The Food and Drug Administration has approved abaloparatide (Tymlos) for postmenopausal women with osteoporosis at high risk for fracture.

Abaloparatide was approved based on 18-month results from the ACTIVE trial and 6-month results from the ACTIVExtend trial. Patients in the ACTIVE trial showed an relative risk reduction of 86% for new vertebral fractures and 43% for nonvertebral fractures, compared with placebo, according to a statement from manufacturer Radius Health. Results were similar regardless of age, years since menopause, presence or absence of prior fracture (vertebral or nonvertebral), and bone mineral density at baseline.

FDA icon Courtesy Wikimedia Commons/FitzColinGerald/Creative Commons License
Common adverse events with abaloparatide include hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain, and vertigo. Abaloparatide was shown to increase risk for osteosarcoma in rats, with higher doses further increasing risk. While it is not known whether abaloparatide will cause osteosarcoma in humans, usage of Tymlos in patients at increased risk for osteosarcoma is not recommended.

Find the full statement on the Radius Health website.

Recommended Reading

Romosozumab, coming ACR guidelines mark recent high points in osteoporosis
MDedge ObGyn
Early estrogen likely prevents bone fractures in Turner syndrome
MDedge ObGyn
One-time AMH level predicts rapid perimenopausal bone loss
MDedge ObGyn
VIDEO: Romosozumab bested teriparatide in hip BMD transitioning from bisphosphonates
MDedge ObGyn
Odanacatib reduced fractures but upped stroke risk
MDedge ObGyn
NAMS hormone therapy guidelines stress individualized treatment
MDedge ObGyn
Study highlights need to address vitamin D deficiency in epilepsy patients
MDedge ObGyn
Bone fractures more likely to occur in psoriasis, PsA patients
MDedge ObGyn
New guidance: Bone health is front and center in functional hypothalamic amenorrhea care
MDedge ObGyn
Study shows no adverse events with long-term denosumab in postmenopausal women
MDedge ObGyn